J Periodontal Implant Sci.  2018 Aug;48(4):251-260. 10.5051/jpis.2018.48.4.251.

Association of chairside salivary aMMP-8 findings with periodontal risk assessment parameters in patients receiving supportive periodontal therapy

• Schmalz G
• Kummer MK
• Kottmann T
• Rinke S
• Haak R
• Krause F
• Schmidt J
• Ziebolz D

• KMID: 2465390
• DOI: http://doi.org/10.5051/jpis.2018.48.4.251

Abstract

PURPOSE
The aim of this retrospective cross-sectional study was to evaluate whether salivary findings of active matrix-metalloproteinase 8 (aMMP-8) chairside (point of care; POC) tests were associated with periodontal risk assessment parameters in patients receiving supportive periodontal therapy (SPT).
METHODS
A total of 125 patients receiving regular SPT were included, and their records were examined. The following inclusion criteria were used: a diagnosis of chronic periodontitis, at least 1 non-surgical periodontal treatment (scaling and root planning) with following regular SPT (minimum once a year), at least 6 remaining teeth, and clinical and aMMP-8 findings that were obtained at the same appointment. In addition to anamnestic factors (e.g., smoking and diabetes), oral hygiene indices (modified sulcus bleeding index [mSBI] and approximal plaque index), periodontal probing depth simultaneously with bleeding on probing, and dental findings (number of decayed, missing, and filled teeth) were recorded. Salivary aMMP-8 levels were tested using a commercial POC test system (Periomarker, Hager & Werken, Duisburg, Germany). Statistical analysis was performed using the t-test, Mann-Whitney U test, Fisher's exact test, and χ2 test, as appropriate (P < 0.05).
RESULTS
Only the mSBI was significantly associated with positive salivary aMMP-8 findings (aMMP-8 positive: 27.8%±20.9% vs. aMMP-8 negative: 18.0%±14.5%; P = 0.017). No significant associations were found between aMMP-8 and smoking, diabetes, periodontal parameters, or parameters related to the maintenance interval (P > 0.05).
CONCLUSIONS
Salivary aMMP-8 chairside findings were not associated with common parameters used for periodontal risk assessment in patients receiving SPT. The diagnostic benefit of POC salivary aMMP-8 testing in risk assessment and maintenance interval adjustment during SPT remains unclear.

Keyword

Maintenance; Metalloproteinase (aMMP-8); Periodontitis; Risk assessment; Supportive periodontal therapy

MeSH Terms

Chronic Periodontitis
Cross-Sectional Studies
Diagnosis
Hemorrhage
Humans
Oral Hygiene Index
Periodontitis
Retrospective Studies
Risk Assessment*
Smoke
Smoking
Tooth
Smoke

Reference

1. Frencken JE, Sharma P, Stenhouse L, Green D, Laverty D, Dietrich T. Global epidemiology of dental caries and severe periodontitis - a comprehensive review. J Clin Periodontol. 2017; 44:Suppl 18. S94–S105.

2. Jordan RA, Micheelis W. The fifth German oral health study (DMS V). Köln: Institut der Deutschen Zahnärzte;2016. [in German].

3. Renvert S, Persson GR. Supportive periodontal therapy. Periodontol 2000. 2004; 36:179–195.

4. Lee CT, Huang HY, Sun TC, Karimbux N. Impact of patient compliance on tooth loss during supportive periodontal therapy: a systematic review and meta-analysis. J Dent Res. 2015; 94:777–786.

5. Armitage GC, Xenoudi P. Post-treatment supportive care for the natural dentition and dental implants. Periodontol 2000. 2016; 71:164–184.

6. Farooqi OA, Wehler CJ, Gibson G, Jurasic MM, Jones JA. Appropriate recall interval for periodontal maintenance: a systematic review. J Evid Based Dent Pract. 2015; 15:171–181.

7. Lang NP, Tonetti MS. Periodontal risk assessment (PRA) for patients in supportive periodontal therapy (SPT). Oral Health Prev Dent. 2003; 1:7–16.

8. Costa FO, Cota LO, Lages EJ, Lima Oliveira AP, Cortelli SC, Cortelli JR, et al. Periodontal risk assessment model in a sample of regular and irregular compliers under maintenance therapy: a 3-year prospective study. J Periodontol. 2012; 83:292–300.

9. Lang NP, Tonetti MS. Periodontal diagnosis in treated periodontitis. Why, when and how to use clinical parameters. J Clin Periodontol. 1996; 23:240–250.

10. Sorsa T, Tjäderhane L, Konttinen YT, Lauhio A, Salo T, Lee HM, et al. Matrix metalloproteinases: contribution to pathogenesis, diagnosis and treatment of periodontal inflammation. Ann Med. 2006; 38:306–321.

11. Sorsa T, Tjäderhane L, Salo T. Matrix metalloproteinases (MMPs) in oral diseases. Oral Dis. 2004; 10:311–318.

12. Golub LM, Payne JB, Reinhardt RA, Nieman G. Can systemic diseases co-induce (not just exacerbate) periodontitis? A hypothetical “two-hit” model. J Dent Res. 2006; 85:102–105.

13. Kraft-Neumärker M, Lorenz K, Koch R, Hoffmann T, Mäntylä P, Sorsa T, et al. Full-mouth profile of active MMP-8 in periodontitis patients. J Periodontal Res. 2012; 47:121–128.

14. Söder B, Jin LJ, Wickholm S. Granulocyte elastase, matrix metalloproteinase-8 and prostaglandin E2 in gingival crevicular fluid in matched clinical sites in smokers and non-smokers with persistent periodontitis. J Clin Periodontol. 2002; 29:384–391.

15. Mäntylä P, Stenman M, Kinane D, Salo T, Suomalainen K, Tikanoja S, et al. Monitoring periodontal disease status in smokers and nonsmokers using a gingival crevicular fluid matrix metalloproteinase-8-specific chair-side test. J Periodontal Res. 2006; 41:503–512.

16. Sorsa T, Tervahartiala T, Leppilahti J, Hernandez M, Gamonal J, Tuomainen AM, et al. Collagenase-2 (MMP-8) as a point-of-care biomarker in periodontitis and cardiovascular diseases. Therapeutic response to non-antimicrobial properties of tetracyclines. Pharmacol Res. 2011; 63:108–113.

17. Zhang L, Li X, Yan H, Huang L. Salivary matrix metalloproteinase (MMP)-8 as a biomarker for periodontitis: a PRISMA-compliant systematic review and meta-analysis. Medicine (Baltimore). 2018; 97:e9642.

18. Izadi Borujeni S, Mayer M, Eickholz P. Activated matrix metalloproteinase-8 in saliva as diagnostic test for periodontal disease? A case-control study. Med Microbiol Immunol (Berl). 2015; 204:665–672.

19. Heikkinen AM, Nwhator SO, Rathnayake N, Mäntylä P, Vatanen P, Sorsa T. Pilot study on oral health status as assessed by an active matrix metalloproteinase-8 chairside mouthrinse test in adolescents. J Periodontol. 2016; 87:36–40.

20. Schmidt J, Guder U, Kreuz M, Löffler M, Kiess W, Hirsch C, et al. aMMP-8 in correlation to caries and periodontal condition in adolescents-results of the epidemiologic LIFE child study. Clin Oral Investig. 2018; 22:449–460.

21. Armitage GC. Development of a classification system for periodontal diseases and conditions. Ann Periodontol. 1999; 4:1–6.

22. World Health Organization. Oral health surveys: basic methods. 4th ed. Geneva: World Health Organization;1997.

23. Mühlemann HR, Son S. Gingival sulcus bleeding--a leading symptom in initial gingivitis. Helv Odontol Acta. 1971; 15:107–113.

24. Lange DE, Plagmann HC, Eenboom A, Promesberger A. Clinical methods for the objective evaluation of oral hygiene. Dtsch Zahnarztl Z. 1977; 32:44–47.

25. Sorsa T, Gursoy UK, Nwhator S, Hernandez M, Tervahartiala T, Leppilahti J, et al. Analysis of matrix metalloproteinases, especially MMP-8, in gingival creviclular fluid, mouthrinse and saliva for monitoring periodontal diseases. Periodontol 2000. 2016; 70:142–163.

26. Lorenz K, Keller T, Noack B, Freitag A, Netuschil L, Hoffmann T. Evaluation of a novel point-of-care test for active matrix metalloproteinase-8: agreement between qualitative and quantitative measurements and relation to periodontal inflammation. J Periodontal Res. 2017; 52:277–284.

27. Rathnayake N, Gieselmann DR, Heikkinen AM, Tervahartiala T, Sorsa T. Salivary diagnostics-point-of-care diagnostics of MMP-8 in dentistry and medicine. Diagnostics (Basel). 2017; 7:7.

28. Ramseier CA, Kinney JS, Herr AE, Braun T, Sugai JV, Shelburne CA, et al. Identification of pathogen and host-response markers correlated with periodontal disease. J Periodontol. 2009; 80:436–446.

29. Mäntylä P, Stenman M, Kinane DF, Tikanoja S, Luoto H, Salo T, et al. Gingival crevicular fluid collagenase-2 (matrix metalloproteinase-8) test stick for chair-side monitoring of periodontitis. J Periodontal Res. 2003; 38:436–439.

30. Mullins JM, Even JB, White JM. Periodontal management by risk assessment: a pragmatic approach. J Evid Based Dent Pract. 2016; 16:Suppl. 91–98.

31. Lyle DM. Risk assessment a key to periodontal health promotion and disease prevention. Compend Contin Educ Dent. 2014; 35:392–396.

32. Lang NP, Suvan JE, Tonetti MS. Risk factor assessment tools for the prevention of periodontitis progression a systematic review. J Clin Periodontol. 2015; 42:Suppl 16. S59–S70.

33. Ito H, Numabe Y, Sekino S, Murakashi E, Iguchi H, Hashimoto S, et al. Evaluation of bleeding on probing and gingival crevicular fluid enzyme activity for detection of periodontally active sites during supportive periodontal therapy. Odontology. 2014; 102:50–56.

34. Sorsa T, Mantyla P, Tervahartiala T, Pussinen PJ, Gamonal J, Hernandez M. Matrix metalloproteinase activation in diagnostics of periodontitis and systemic inflammation. J Clin Periodontol. 2011; 38:817–819.

35. Hernández M, Dutzan N, García-Sesnich J, Abusleme L, Dezerega A, Silva N, et al. Host-pathogen interactions in progressive chronic periodontitis. J Dent Res. 2011; 90:1164–1170.

36. Rai B, Kharb S, Jain R, Anand SC. Biomarkers of periodontitis in oral fluids. J Oral Sci. 2008; 50:53–56.